AEterna Zentaris Inc. (AEZS, AEZ.TO) announced that its partner Keryx Biopharmaceuticals Inc. (KERX) reported updated efficacy and safety data as well as new survival data on the clinical activity of perifosine or KRX-0401 in combination with bortezomib, or Velcade, (+/- dexamethasone) in patients with relapsed/refractory multiple myeloma.
Keryx is AEterna Zentaris' partner and licensee for perifosine in the United States, Canada and Mexico. Perifosine is also out-licensed to Handok in South Korea while AEterna Zentaris retains rights for the rest of the world.
Eighty-four patients with relapsed/refractory multiple myeloma were enrolled in a combined Phase 1/2 study. Seventy-three patients were evaluable for efficacy. Evaluable patients are defined as those patients who had received at least two cycles of therapy on the combination of perifosine with bortezomib. Of the 73 evaluable patients, 53 patients (73%) were previously refractory to bortezomib (defined as progression on or within 60 days of treatment to a bortezomib-based regimen), including 44 patients who were refractory to the combination of bortezomib + dexamethasone. Twenty evaluable patients (27%) were relapsed to a prior bortezomib-based regimen.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.